Richard L. Hoover
Vanderbilt University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Richard L. Hoover.
Journal of Clinical Investigation | 1992
K Takahashi; T M Nammour; M Fukunaga; J. Ebert; J D Morrow; L J Roberts nd; Richard L. Hoover; Kamal F. Badr
8-epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) and related compounds are novel prostanoid produced by a noncyclooxygenase mechanism involving lipid peroxidation. Renal ischemia-reperfusion injury increased urinary excretion of these compounds by 300% over baseline level. Intrarenal arterial infusion at 0.5, 1, and 2 micrograms/kg per min induced dose-dependent reductions in glomerular filtration rate (GFR) and renal plasma flow, with renal function ceasing at the highest dose. Micropuncture measurements (0.5 microgram/kg per min) revealed a predominant increase in afferent resistance, resulting in a decrease in transcapillary hydraulic pressure difference, and leading to reductions in single nephron GFR and plasma flow. These changes were completely abolished or reversed by a TxA2 receptor antagonist, SQ 29,548. Competitive radioligand binding studies demonstrated that 8-epi-PGF2 alpha is a potent competitor for [3H]SQ 29,548 binding to rat renal arterial smooth muscle cells (RASM) in culture. Furthermore, addition of 8-epi-PGF2 alpha to RASM or isolated glomeruli was not associated with stimulation of arachidonate cyclooxygenase products. Therefore, 8-epi-PGF2 alpha is a potent preglomerular vasoconstrictor acting principally through TxA2 receptor activation. These findings may explain, in part, the beneficial effects of antioxidant therapy and TxA2 antagonism observed in numerous models of renal injury induced by lipid peroxidation.
Journal of Clinical Investigation | 1988
Raymond C. Harris; Richard L. Hoover; Harry R. Jacobson; Kamal F. Badr
Epidermal growth factor (EGF), an endogenous mitogenic peptide, has recently been shown to be a potent vasoconstrictor of vascular smooth muscle. In view of its potential role in proliferative and inflammatory renal glomerular diseases, we examined the effects of EGF both on cultured rat mesangial cells and on in vivo glomerular hemodynamics. Mesangial cells possess specific, saturable EGF receptors of differing affinities, with Kds of 0.1 and 1.7 nM, respectively. EGF produced a rapid increase in intracellular pH of 0.12 +/- 0.01 pH U, which was sodium dependent and amiloride inhibitable. The addition of EGF to mesangial cells cultured on either glass or dimethylpolysiloxane substratum induced reproducible cell contraction. Intrarenal EGF infusion did not affect systemic blood pressure or hematocrit but reversibly decreased GFR and renal blood flow from 4.19 +/- 0.33 to 3.33 +/- 0.26 and from 1.17 +/- 0.09 to 0.69 +/- 0.07 ml/min, respectively. Glomerular micropuncture confirmed decreases in single nephron plasma flow and in single nephron GFR (from 142 +/- 9 to 98 +/- 8 and from 51.6 +/- 11.7 to 28.5 +/- 3.5 nl/min, respectively) which were due to significant increases in both pre- and postglomerular arteriolar resistances (from 1.97 +/- 0.31 to 2.65 +/- 0.36 and from 1.19 +/- 0.11 to 2.00 +/- 0.15 10(10) dyn.s.cm-5 respectively) and to a significant decrease in the ultrafiltration coefficient, Kf, which fell from 0.100 +/- 0.019 to 0.031 +/- 0.007 nl/(s.mmHg). These studies demonstrate that mesangial cells possess specific receptors for EGF, and exposure of these cells to physiologic concentrations of EGF results in an in vitro functional response characterized by activation of Na+/H+ exchange and by resultant intracellular alkalinization, as well as by cell contraction. EGF administration in vivo significantly reduces the glomerular capillary ultrafiltration coefficient, Kf, which, in combination with EGF-induced constriction of both preglomerular and postglomerular arterioles, results in acute major reductions in the rates of glomerular filtration and perfusion.
FEBS Letters | 2002
Robert W. Tilghman; Richard L. Hoover
Here we present data supporting the role of lipid rafts in endothelial cells during leukocyte adhesion. Following adhesion of THP‐1 cells or antibody‐mediated clustering, both E‐selectin and intercellular adhesion molecule‐1 (ICAM‐1) partitioned into the detergent‐insoluble portion of the endothelial cellular lysate. Sucrose gradient centrifugation revealed the partitioning of clustered E‐selectin and ICAM‐1 with the low‐density fraction where they co‐fractionated with src family kinases, markers of lipid rafts. Depleting the plasma membrane of cholesterol inhibited clustering of adhesion molecules following their antibody‐induced crosslinking and inhibited their association with src kinases. Thus, our data suggest that E‐selectin and ICAM‐1 associate with lipid rafts in human endothelial cells following leukocyte adhesion.
The FASEB Journal | 2002
Robert W. Tilghman; Richard L. Hoover
Adhesion molecules such as E‐selectin and intercellular adhesion molecule‐1 (ICAM‐1) expressed on endothelial cells (ECs) at sites of inflammation play an important role in the recruitment of leukocytes from the bloodstream into extravascular tissue. However, little is known about the signaling pathways that are initiated in ECs following adhesion molecule engagement. Here, we report that an 85‐kDa protein becomes tyrosine phosphorylated in human ECs following leukocyte adhesion or upon antibody‐induced clustering of E‐selectin or ICAM‐1. Through immunoprecipitation experiments, this protein was identified as cortactin, a cytoskeleton‐binding molecule and prominent src substrate involved in cell adhesion. Following adhesion molecule clustering, cortactin phosphorylation was inhibited by the src family kinase inhibitor PP2. Both src and tyrosine‐phosphorylated cortactin were found to be associated with E‐selectin and ICAM‐1 following adhesion of antibody‐coated beads to ECs. PP2 did not inhibit the association of cortactin with E‐selectin and ICAM‐1; however, PP2 inhibited adhesion between paraformaldehyde‐fixed THP‐1 cells and ECs. This decrease in adhesion correlated with inhibition of adhesion molecule clustering on PP2‐treated ECs at sites of THP‐1 attachment. These findings implicate src and cortactin as mediators of leukocyte/EC interactions at sites of inflammation by regulating adhesion molecule clustering on ECs.
Biochemical Pharmacology | 1992
Kristina E. Hill; Robert W. Hunt; Rhoda Jones; Richard L. Hoover; Raymond F. Burk
Metabolism of nitroglycerin (GTN) in the vascular smooth muscle is required for the drug to be effective in the treatment of angina pectoris and congestive heart failure. The usefulness of GTN is limited by the development of tolerance to the drug. The metabolism of GTN was studied in its target tissue, vascular smooth muscle. Inorganic nitrite was produced by cultured smooth muscle cells when GTN was added to the culture dish. Nitrite production increased with increasing GTN concentration and with incubation time. The enzymatic nature of GTN metabolism to nitrite was assessed by enzyme inhibition studies. Indocyanine green, a non-substrate inhibitor of glutathione S-transferase, inhibited GTN metabolism by smooth muscle cells. Cellular glutathione is also involved in GTN metabolism by the smooth muscle cell. Pretreatment with phorone, a glutathione S-transferase substrate, depleted cellular glutathione and decreased nitrite production from GTN. Pretreatment with buthionine sulfoximine, inhibitor of gamma-glutamylcysteine synthetase, decreased intracellular glutathione and caused decreased GTN metabolism in smooth muscle cells. Removal of cysteine from the smooth muscle cell incubation medium in combination with buthionine sulfoximine pretreatment decreased GTN metabolism to a lower level than buthionine sulfoximine pretreatment alone. This study shows that glutathione S-transferase and glutathione are involved in GTN metabolism by cultured smooth muscle cells.
Atherosclerosis | 1989
James B. Atkinson; Richard L. Hoover; Karen K. Berry
Homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits are used widely to study atherosclerosis, but the WHHL heterozygous rabbit has received little attention. To study their potential as a model for atherosclerosis, heterozygous WHHL and New Zealand white (NZW) rabbits were fed diets containing 0%, 0.5% and 1.0% cholesterol. Plasma lipids were analyzed at 0, 4, 8, 12, 16 and 24 weeks, and animals were killed at 12 and 24 weeks. Plasma cholesterol levels were significantly higher in cholesterol-fed WHHL heterozygotes at 8 weeks compared with NZW rabbits, but no differences were apparent at other times. Atherosclerotic plaques in the aortas of cholesterol-fed WHHL heterozygous rabbits differed from those in NZW rabbits, in that the WHHL had complicated lesions with necrosis, cholesterol clefts, fibrous caps and calcification, similar to that found in humans and homozygous WHHL rabbits. In contrast, NZW rabbits had predominantly foam cell lesions. Heterozygous WHHL rabbits also had less extensive extravascular foam cell deposits. Our results suggest that the cholesterol-fed heterozygous WHHL rabbit may provide a promising model for studying the pathogenesis of atherosclerosis.
Pediatric Research | 1997
Jessica G. Klekamp; Kasia Jarzecka; Richard L. Hoover; Marshall L Summar; Nicole Redmond; Elizabeth A. Perkett
Chronic lung disease in neonates results from both lung injury and inadequate repair processes. Little is known about the growth factors involved in lung injury and repair, but vascular endothelial growth factor (VEGF) has recently been reported in several animal models of lung injury. VEGF is an endothelial cell-specific mitogen, which is also known as vascular permeability factor because of its ability to induce vascular leak in some tissues. Chronic lung disease is complicated by increased vascular permeability, which can be improved by avoidance of hypoxia and in some cases by dexamethasone therapy. In many cells, hypoxia stimulates VEGF expression. Also, in some cases, dexamethasone blocks VEGF expression. This study examined the role of hypoxia and dexamethasone in regulating the expression of VEGF in pulmonary artery smooth muscle cells. An ovine VEGF cDNA fragment (453 bp) was cloned and found to be highly homologous to known human sequences for VEGF165. Sheep pulmonary artery smooth muscle cells were cultured and exposed to room air, hypoxia, and dexamethasone, alone or in combination for 6 h. At baseline these cells expressed VEGF mRNA at approximately 3.9 kb. The half-life of VEGF mRNA in the smooth muscle cells was 171 min, more than 3-fold longer than previous reports for epithelial cells. Exposure to hypoxia caused a 3-fold increase in mRNA abundance, primarily through transcriptional up-regulation. Dexamethasone blocked the hypoxia-induced increase in VEGF mRNA. The results demonstrate that hypoxia and dexamethasone are regulators of VEGF expression in ovine pulmonary artery smooth muscle cells. It is not known whether VEGF derived from these cells is involved in lung injury and/or normal homeostatsis.
FEBS Letters | 1992
Naomasa Makitala; Colin D. Funku; Enyu Imaic; Richard L. Hoover; Kamal F. Badra
We isolated a cDNA encoding rat leukotriene A4 (LTA4) hydrolase from mesangial cells by the polymerase chain reaction according to the human amino acid sequence. The deduced amino acid sequence shows that rat LTA, hydrolase is a 609 amino acid protein with an M, 69 kDa. Comparison of human LTA4 hydrolase revealed 93% homology, and include zinc‐binding motifs of aminopeptidases. COS‐7 cells transfected with the cDNA revealed substantial LTA4 hydrolase activity, and their activities were abolished by preincubation with captopril, representing the first reported cDNA expression of recombinant enzyme in mammalian cells. RNA blot analysis indicated that LTA4 hydrolase was expressed in glomerular endothelial, epithelial and mesangial cells.
Diabetologia | 1990
Michael Z. Gilcrease; Richard L. Hoover
SummaryNon-enzymatic glycosylation of proteins is thought to play an important role in the development of diabetic vascular disease. Advanced glycosylation end products have been shown to accumulate on basement membranes and collagen in diabetes, and receptors for such adducts have recently been found on murine macrophages. We have observed that human monocytes activated by endotoxin express receptors for advanced glycosylation end products of similar affinity and number as has been previously reported for murine macrophages. In addition, there is an increased adherence of activated human monocytes to a nonenzymatically glycosylated albumin substrate, and such adhesion can be competitively inhibited up to 50% by soluble, non-enzymatically glycosylated albumin. We suggest that increased adherence of activated monocytes to non-enzymatically glycosylated proteins in the vessel wall may result in monocyte stimulation and/or local monocyte accumulation and thereby contribute to vascular disease in diabetes.
Endothelium-journal of Endothelial Cell Research | 2006
LiChun Zhou; MingJian Shi; ZhongMao Guo; Wendy Brisbon; Richard L. Hoover; Hong Yang
Lysophosphatidylcholine (LPC) and 7-ketocholesterol (7-KC) are two key components of oxidized low-density lipoprotein (oxLDL) and have been shown to injure endothelial cells derived from various species. This report examines LPC- and 7-KC-induced cell death in mouse aorta endothelial cells (MAECs). The presence and the mechanism of cell death were assessed with morphological criteria, Hoechst 33342 and propidium iodide fluorescence staining, and caspase-3 activity. The authors observed that 7-KC induced cell shrinkage, nuclear condensation, and caspase-3 activity. In contrast, LPC induced membrane rupture, nuclear expansion, and cell lysis. In addition, 7-KC induced a transient increase, whereas LPC induced a sustained increase in intracellular Ca2+ levels and production of reactive oxygen species (ROS). Antioxidants and calcium antagonists attenuated both 7-KC- and LPC-induced cell death. These findings suggest that 7-KC and LPC injure MAECs through differential mechanisms; LPC induces necrosis, 7-KC induces apoptosis, and the increase in intracellular Ca2+ levels and production of ROS are common mechanisms for these cytotoxic injuries.